Concord Wealth Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Concord Wealth Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-59	Closed	-$1K	–	1367
2021 Q3	$1K	Hold	59	–	–	﹤0.01%	892
2021 Q2	$2K	Hold	59	–	–	﹤0.01%	933
2021 Q1	$2K	Hold	59	–	–	﹤0.01%	870
2020 Q4	$1K	Buy	+59	New	+$1.3K	﹤0.01%	676

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Concord Wealth Partners's DRNA Position: Q4 2021 in Review

Concord Wealth Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 59 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in DRNA in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Concord Wealth Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Concord Wealth Partners sold 59 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1K.
Concord Wealth Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
Concord Wealth Partners's Dicerna Pharmaceuticals, Inc. position peaked at $2K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Concord Wealth Partners's 13F filing for Q4 2021, filed 21 Jan 2022.